Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference
LD Micro Invitational |
|||
Date: | Tuesday, June 6th | ||
Time: | 4:00 pm Pacific Time | ||
Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
Jefferies 2017 Global Healthcare Conference | |||
Date: | Thursday, June 8th | ||
Time: | 4:00pm Eastern Time | ||
Presenter: | Lee Golden, MD, Chief Medical Officer | ||
Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
Webcast: | http://wsw.com/webcast/jeff105/gemp |
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact:Andrew McDonald , Ph.D.LifeSci Advisors, LLC (646) 597-6987Jeff Mathiesen , CFOGemphire Therapeutics Inc. (734)-245-1700